Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 15Rectal Neoplasms 4Colonic Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Biliary Tract Neoplasms 2Rhabdomyosarcoma 1Rare Tumour 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Neuroblastoma 1Neoplasms, Second Primary 1Neoplasm, Residual 1Medulloblastoma 1Lung Neoplasms 1Locally Advanced Low Rectal Adenocarcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1CRC 1Biliary Cancer Metastatic 1Appendiceal Neoplasms 1Advanced Malignant Neoplasm 1Advanced Esophageal Carcinoma 1

Interventions

Paclitaxel 1Irinotecan 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Esophageal Carcinoma × Irinotecan × Clear all
NCT06745193 2024-12-20

A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

Peking University

Phase 2 Not yet recruiting
63 enrolled
Gastrointestinal

Advanced Esophageal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡